Dr. David S. Dickens
Claim this profileUniversity of Iowa/Holden Comprehensive Cancer Center
Expert in Brain Tumor
Expert in Tumors
63 reported clinical trials
121 drugs studied
About David S. Dickens
Education:
- Earned an MD (Doctor of Medicine).
Experience:
- Serves as a Clinical Professor of Pediatrics at the University of Iowa.
- Holds the position of Clinical Director of Pediatric Oncology at the University of Iowa.
- UI Dance Marathon Endowed Chair in Pediatric Oncology, focusing on Clinical and Translational Research.
- Active Full Member of the Cancer Epidemiology and Population Science program at the University of Iowa Holden Comprehensive Cancer Center.
- Engaged in numerous clinical trials and research projects within pediatric oncology.
Area of expertise
1Brain Tumor
Global LeaderStage I
Stage II
Stage IV
2Tumors
Global LeaderStage I
Stage IV
Stage II
Affiliated Hospitals
Clinical Trials David S. Dickens is currently running
Genetic Testing-Directed Therapy
for Pediatric Cancer
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Recruiting1 award Phase 214 criteria
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
More about David S. Dickens
Clinical Trial Related9 years of experience running clinical trials · Led 63 trials as a Principal Investigator · 27 Active Clinical TrialsTreatments David S. Dickens has experience with
- Cyclophosphamide
- Radiation Therapy
- Etoposide
- Doxorubicin Hydrochloride
- Nivolumab
- Methotrexate
Breakdown of trials David S. Dickens has run
Brain Tumor
Tumors
Lymphoma
Neuroblastoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David S. Dickens specialize in?
David S. Dickens focuses on Brain Tumor and Tumors. In particular, much of their work with Brain Tumor has involved Stage I patients, or patients who are Stage II.
Is David S. Dickens currently recruiting for clinical trials?
Yes, David S. Dickens is currently recruiting for 26 clinical trials in Iowa City Iowa. If you're interested in participating, you should apply.
Are there any treatments that David S. Dickens has studied deeply?
Yes, David S. Dickens has studied treatments such as Cyclophosphamide, Radiation Therapy, Etoposide.
What is the best way to schedule an appointment with David S. Dickens?
Apply for one of the trials that David S. Dickens is conducting.
What is the office address of David S. Dickens?
The office of David S. Dickens is located at: University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa 52242 United States. This is the address for their practice at the University of Iowa/Holden Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.